Kim M. Keeling, Ph.D.
Affiliations: | 2000 | University of Alabama, Birmingham, Birmingham, AL, United States |
Area:
Genetics, Molecular BiologyGoogle:
"Kim Keeling"Parents
Sign in to add mentorDavid M. Bedwell | grad student | 2000 | UAB | |
(Suppression of premature stop mutations using aminoglycosides.) |
BETA: Related publications
See more...
Publications
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
Siddiqui A, Saxena A, Echols J, et al. (2023) RNA binding proteins PTBP1 and HNRNPL regulate mRNA decay. Heliyon. 9: e22281 |
Staedtke V, Anstett K, Bedwell D, et al. (2023) Gene-targeted therapy for neurofibromatosis and schwannomatosis: The path to clinical trials. Clinical Trials (London, England). 17407745231207970 |
Chen J, Thrasher K, Fu L, et al. (2023) The synthetic aminoglycoside ELX-02 induces readthrough of G550X-CFTR producing super-functional protein that can be further enhanced by CFTR modulators. American Journal of Physiology. Lung Cellular and Molecular Physiology |
Siddiqui A, Dundar H, Sharma J, et al. (2023) Triamterene Functions as an Effective Nonsense Suppression Agent for MPS I-H (Hurler Syndrome). International Journal of Molecular Sciences. 24 |
Wang D, Xue X, Gunn G, et al. (2022) Ataluren suppresses a premature termination codon in an MPS I-H mouse. Journal of Molecular Medicine (Berlin, Germany) |
Sharma J, Du M, Wong E, et al. (2021) A small molecule that induces translational readthrough of CFTR nonsense mutations by eRF1 depletion. Nature Communications. 12: 4358 |
Echols J, Siddiqui A, Dai Y, et al. (2020) A regulated NMD mouse model supports NMD inhibition as a viable therapeutic option to treat genetic diseases. Disease Models & Mechanisms |
Echols J, Siddiqui A, Dai Y, et al. (2020) A regulated NMD mouse model supports NMD inhibition as a viable therapeutic option to treat genetic diseases. Disease Models & Mechanisms |
Sharma J, Keeling KM, Rowe SM. (2020) Pharmacological approaches for targeting cystic fibrosis nonsense mutations. European Journal of Medicinal Chemistry. 200: 112436 |
Leier A, Bedwell DM, Chen AT, et al. (2020) Mutation-Directed Therapeutics for Neurofibromatosis Type I. Molecular Therapy. Nucleic Acids. 20: 739-753 |